Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901303 · ClinicalTrials.gov registry record · NA
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
A NA study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00901303 is a NA study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 6 participants.
The verdict
NCT00901303, a NA study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the progression-free survival \[PFS\] at 36 months for patients with Hodgkin lymphoma who achieve a complete metabolic response as demonstrated by a negative fluorodeoxyglucose (FDG)-PET scan after one cycle of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) who undergo abbreviated ABVD chemotherapy (3 cycles).
Interventions
- DRUG ABVD chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-05-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00901303
The ClinicalTrials.gov registry entry for NCT00901303 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABVD chemotherapy is the first listed.
NCT00901303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00901303 about?
NCT00901303 is a clinical study titled "Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma". The primary objective of the study is to determine the progression-free survival \[PFS\] at 36 months for patients with Hodgkin lymphoma who achieve a complete metabolic response as demonstrated by a negative fluorodeoxyglucose (FDG)-PET scan after one cycle of ABVD (adriamycin, bleomycin, vinblasti...
What is the current status of trial NCT00901303?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2008-10. Estimated completion is 2011-05-23.
What interventions are being tested in trial NCT00901303?
The interventions under investigation include: ABVD chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00901303?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.